5. Culturally Competent Care for Substance Users Diagnosed with HIV Disease
Other Common Comorbidities Among HIV-Positive Substance Users
In addition to the risk of HIV infection, substance users can also be at increased for a number of other comorbidities, many of them infectious. [NIDA Drug Abuse, Linked Epidemics: Drug Abuse and HIV/AIDS, 2005]
Hepatitis. Up to 90% of HIV-positive
IDUs may be infected with hepatitis C virus (HCV), with most becoming
infected within 3 years after starting injection drug use. Hepatitis B virus (HBV) also commonly occurs among IDUs. Chronic infection with HCV or HBV can result in cirrhosis or hepatocellular carcinoma. The interaction between HIV infection and HCV infection has not been completely elucidated, but the course of HCV infection is accelerated in coinfected individuals, with higher rates of progressive liver disease and death vs those infected with HCV alone.
Tuberculosis. Persons with latent tuberculosis (TB) infection do not present symptoms, may never develop active disease, and cannot transmit TB, but they should received prophylactic therapy to prevent the emergence of active disease and the subsequent risk of transmission. Higher rates of latent TB infection occur in IDUs, and, due to HIV-related reduced immune function, individuals coinfected with HIV and latent TB are at increased risk of developing active TB and becoming highly infectious.
Sexually transmitted infections. IDUs experience higher rates of STIs, including syphilis, chlamydia, trichomoniasis, gonorrhea, and genital herpes.
Bacterial infections. A variety of bacterial infections commonly occur in IDUs, including:
- Cellulitis
- Abscesses
- Endocarditis
- Pneumonia
Neurologic disorders. Central nervous system disorders sometimes experienced by HIV-positive IDUs can include the parasitic infection toxoplasmosis and the fungal infection cryptococcosis.
Renal disease. Kidney disorders experienced by HIV-infected substance users can include HIV-associated nephropathy and chronic renal disease.